Clinical Trial Update: NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy [Phase 3]

View source ↗

Summary

Phase 3 NEURO-TTRansform study evaluating the efficacy and safety of Eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloid Polyneuropathy

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2024-12-10